Skip to main content

Adiponectin in psoriasis and its comorbidities: a review


Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by abnormal T cell activation and excessive proliferation of keratinocytes. In addition to skin manifestations, psoriasis has been associated with multiple metabolic comorbidities, such as obesity, insulin resistance, and diabetes. An increasing amount of evidence has highlighted the core role of adipokines in adipose tissue and the immune system. This review focus on the role of adiponectin in the pathophysiology of psoriasis and its comorbidities, highlighting the future research avenues.


Psoriasis is a chronic skin inflammation involving hyperkeratosis and parakeratosis. It usually manifests as well-defined, raised, red plaques covered by silvery scales [1, 2] (Table 1). In the latest global epidemiological survey, the prevalence of psoriasis varied from 0.14% in East Asia to 1.99% in Australasia. The prevalence of psoriasis was also high in Europe and America [7]. The prevalence of psoriasis in Europe ranges from 0.6 to 6.5% and 3.15% in the US [8]. In China, the prevalence of psoriasis ranges from 0.44 to 0.54%, with 97% of patients having psoriasis vulgaris and 28% of patients reporting a family history of psoriasis [9] (Table 2). The relationship between psoriasis incidence and age appears to be relatively linear [12]. Psoriasis, mediated by T cells and dendritic cells, is closely related to the immune system and various clinical manifestations represent the activation of different components of the immune system. The adaptive immune system is mainly involved in chronic plaque psoriasis, while innate immune and autoinflammatory reactions play key roles in generalized pustular psoriasis [16]. Psoriasis vulgaris is considered one of the easiest human diseases to study [17]. Patients with psoriasis have a higher incidence of severe infections than those without psoriasis [18]. Furthermore, it has been shown that psoriasis itself may affect other organs [19]. For example, psoriasis is an important predictor of advanced liver fibrosis, which is not linked to age, sex, body mass index (BMI), hypertension or diabetes [20].

Table 1 The feature of different types of psoriasis [3,4,5,6]
Table 2 The incidence of psoriasis in all ages in different countries

Adipose tissue participates in many physiological and metabolic processes in the body and acts as an energy reserve and an endocrine organ. Although fat cells are the main component of adipose tissues, they also include immune cells (such as T lymphocytes and macrophages) [21]. Previous studies have reported that adipose tissue has important immune functions and may be a major source of pro-inflammatory mediators, which promote the development of chronic inflammation, insulin resistance and atherosclerosis, all of which are associated with metabolic abnormalities [22]. The concept of ‘adipokine’ was first introduced when leptin was found in white fat [23]. By producing adipokines, especially adiponectin, adipose tissue is involved in many metabolic processes, including energy storage and temperature regulation. Adiponectin can also act on monocytes by regulating the polarization and proliferation of macrophages, thereby actively participating in immune responses and reducing T-cell reactivity and B-cell lymphocyte production [24]. Members of the C1q/TNF-related protein (CTRP) family, including adiponectin, play roles in metabolism and immunity [25]. A recent study suggested that adiponectin may also be a lipid carrier. Adiponectin and other CTRPs selectively bind to several anionic phospholipids and sphingolipids via the C1q domain in an oligomerization-dependent fashion, functioning as lipid opsonins [26]. AdipoR1 and AdipoR2 were identified as receptors for adiponectin. They are ubiquitously expressed, but AdipoR1 is more highly expressed in skeletal muscle, while AdipoR2 is more restricted to the liver [27]. Once bound to its receptors, AdipoR1 and R2, adiponectin initiates a series of tissue-dependent signal transduction events, including phosphorylation of adenosine monophosphate protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38 MAPK), and it increases peroxisome proliferator-activated receptor alpha (PPARα) ligand activity, thereby reducing inflammation in various cell types [28]. For example, by inhibiting the nuclear factor κB (NF-κB) signalling pathway, adiponectin has an anti-inflammatory effect [29]. In view of the structural similarities between adiponectin and the CTRP proteins, these receptors may also respond to other CTRP family members [30]. Adiponectin may form heterotrimers with CTRP2 and CTRP9, but these trimers can only be generated when all three proteins are co-expressed in the same cell [31].

Therefore, whether adiponectin plays a key role in psoriasis and the underlying mechanism should be investigated. This review discusses the relationship between adiponectin and psoriasis, including the role of adiponectin in comorbidities, and the potential role of adiponectin in preventing or slowing the progression of psoriasis and its related comorbidities.

Adiponectin and psoriasis

Serum adiponectin and psoriasis

Adiponectin is a 30 kDa monomeric glycoprotein comprised of an N-terminal signal sequence, a nonhomologous or hypervariable region, a collagenous domain containing 22 collagen repeats, and a C-terminal C1q-like globular domain [28, 32]. Previous studies have suggested that adiponectin may be involved in the pathogenesis of psoriasis [33, 34]. Adiponectin plays an anti-inflammatory role in keratinocytes and inhibits the production and activity of pro-inflammatory cytokines, including the interleukin cytokines IL-2, IL-6, IL-8, IL-17 and IL-22; tumour necrosis factor-α (TNF-α); and interferon-γ (IFN-γ) and IFN-g, while increasing the secretion of anti-inflammatory cytokines such as IL-10 [35,36,37]. In T lymphocytes, it was previously found that non-recombinant adiponectin inhibited the production of IL-17, IL-22, TNF-α and IFN-g in Hut102 cells, possibly through AdipoR1, and the expression of adiponectin R1 in psoriatic epidermis was decreased [38]. Most studies have shown lower adiponectin levels in psoriasis patients than in healthy controls [39,40,41]. In experiments with psoriasis patients and control groups, the reduction of adiponectin and IL-10 was the predominant feature, followed by changes in IL-2, IL-12 and IL-17 [42]. Patients with psoriasis have lower plasma adiponectin levels, which may worsen the severity of their skin lesions [43]. Previous documents from 10 years ago revealed that plasma C-reactive protein (CRP) levels are negatively correlated with plasma adiponectin levels, and a significant negative correlation between CRP and adiponectin mRNA levels was also observed in human adipose tissue [44, 45]. However, in subsequent research, adiponectin serum levels were also positively correlated with the sedimentation rate (SR) and CRP levels, which was somewhat puzzling. Previously, the importance of this relationship in the course of psoriasis was unclear, but now it has been demonstrated that plasma adiponectin decreases and CRP increases as metabolic diseases progress [44, 46, 47]. Therefore, the reduction in adiponectin levels is closely related to the occurrence of psoriasis. As an inflammatory factor, CRP participates with various cytokines in the immune response and may play an important role in promoting the development of psoriasis.

Previous research on adiponectin focused on TNF-α and IL-6, which inhibit anti-inflammatory defences, particularly adiponectin levels [45]. Data from human and rodent in vivo studies have shown that adiponectin levels are negatively correlated with TNF-α and IL-6 [48,49,50]. Increased levels of pro-inflammatory cytokines, especially IL-6, in patients with psoriasis may be one of the causes of the decline in adiponectin levels in subcutaneous and visceral adipose tissue [51, 52]. Adiponectin can inhibit TNF-α [53], which can also be negatively regulated by TNF-α in psoriatic patients [54]. Anti-TNF therapy has also been found to decrease IL-6 levels in patients with psoriasis [55]. In addition, upregulation of anti-inflammatory cytokines helps restore the balance between Th (helper T cell) 1, Th17 and Th2 responses in patients with psoriasis [56]. In an AMPK-dependent manner, adiponectin inhibits Th0 cell differentiation into Th1 and Th17 cells [57]. Among its anti-inflammatory effects is inhibition of IL-17A production [58]. Adiponectin-deficient mice suffer from severe psoriasis-like skin inflammation and increased infiltration of IL-17 secreting skin Vγ4 γ δ-T cells, particularly upregulation of the Th17-related cytokines IL-17A, IL-17F and IL-22 [58]. Moreover, adiponectin also inhibits the synthesis and secretion of cytokine IL-17 by human CD4 (+)/CD8 (+) T cells [59] (Fig. 1). Consequently, adiponectin plays a key role in regulating psoriasis by directly inhibiting the secretion of IL-17 by T cells, which suggests new approaches to the study of psoriasis. Similar to adipocytes, sebaceous cells have also been found to differentially express and secrete adipokines. Adiponectin is expressed in human sebaceous glands (SGs), affecting the homeostasis of the dermis and promoting inflammation. Its relationship with systemic inflammation such as psoriasis is an interesting research pathway [68].

Fig. 1

The role of adiponectin in the pathogenesis of psoriasis. Adiponectin is secreted by fat cells and can act on keratinocytes and naive T cells. A decreased adiponectin content leads to increased pro-inflammatory cytokines and decreased anti-inflammatory cytokines [60]. Among these, TNF-α can further affect macrophages and myeloid dendritic cells, resulting in increased secretion of cytokines [60]. In addition, adiponectin increases the number of Vγ4γδT cells. In keratinocytes, adiponectin can activate the E2F1 gene through the AMPK pathway, and the decrease in adiponectin levels leads to reduced E2F1 gene activation, thereby promoting the proliferation of keratinocytes [61,62,63,64]. In addition, SIRT1 can interact with the FoxO family. Downregulation of SIRT1 leads to abnormal transcriptional regulation of genes related to cell proliferation, survival, apoptosis, and metabolism, resulting in abnormal cell apoptosis [65,66,67]. These changes interact with the infiltration of the inflammatory response, which leads to psoriasis

Subgroup and meta-regression analyses have found no significant correlation in terms of age, sex, psoriasis area and severity index (PASI) or study quality score with the expression level of adiponectin in psoriasis [39, 46]. This contrasts with previous findings that adiponectin levels are negatively correlated with PASI [54, 58, 69]. Despite the fact that most reports find the former [33, 50], there are indications that although the PASI score is negatively correlated with adiponectin levels, the correlation is very weak and therefore not clinically relevant [70]. Regarding the contradiction in the correlation between serum adiponectin and PASI, recent articles have shown that adiponectin is significantly reduced in the plasma of patients with mild (PASI< 10) or moderate (PASI< 20) forms of psoriasis, but it does not differ from controls in patients with severe psoriasis (PASI> 20) [46]. There are also articles suggesting that there is no correlation between adiponectin and PASI scores. This may be because most of the study subjects were patients with mild psoriasis, so a low PASI score indicates low disease activity with low TNF-a levels [71], meaning that the degree of correlation could be related to the patient sample selection. For the exact relationship between adiponectin and PASI, a single correlation cannot be used to discuss the overall relationship.

Local adiponectin and psoriasis

There is increasing evidence that adipose tissue is locally involved in the pathophysiology of psoriasis and that dermal adipocytes participate in the steady-state temperature regulation of the skin [72,73,74]. In psoriasis, many different microorganisms play a pathogenic role, including Staphylococcus aureus [75]. Recent observations have found that after S. aureus infects the skin of mice, preadipocytes proliferate rapidly, and mice with impaired adipogenesis have a reduced protective effect against the infection, indicating that dermal adipocytes are also involved in skin protection against infection [76]. At the same time, skin without lesions in psoriasis demonstrates the same upregulation of cathelicidin expression after barrier disruption as the original psoriatic lesions, indicating that this response is local, not systemic [77].

Skin inflammation in patients with psoriasis is restricted to psoriatic plaques. This observation supports a primary local modification of the superficial layer of the subcutaneous white adipose tissue (sWAT) underneath the psoriatic plaques [72, 74]. It has been found that the local concentrations of adiponectin and TNF-α in sWAT were not significantly different between the control group and the psoriasis and/or metabolic syndrome group [73]. Another study found that the local adiponectin levels in the healthy skin and skin lesions of psoriasis patients were substantially lower than those in the control group [58]. The results of the former study may have been caused by the patients discontinuing hormone therapy before biopsy. This may have changed the local concentration of adipokines in the sWAT during the biopsy [73].

Ultrasound elastography can identify the involvement of subcutaneous adipose tissue in patients with plaque psoriasis and it can be used as an effective method to evaluate the early treatment response of patients with plaque psoriasis. The average strain ratio of the psoriasis lesion area was significantly higher than that of the non-lesion area [78]. Effective psoriasis treatment can greatly reduce the WAT hardness under the plaque, making it equivalent to the normal value of non-lesion skin, and this is related to an improvement in skin condition [79]. Therefore, the pathophysiology of psoriasis is not limited to the epidermis but should also include the spatially restricted tissue composite containing the skin and the adjacent WAT. Compared with changes in serum adiponectin levels, whether changes in local adiponectin levels have a greater impact on psoriasis is of interest.

Adiponectin and psoriasis comorbidities

Adiponectin and obesity

Psoriasis has been linked to obesity [80], especially abdominal obesity [81]. Obesity can also exacerbate existing psoriasis [82]. Abdominal obesity has been associated with a substantially low adiponectin level, demonstrated by a negative correlation between adiponectin level and waist circumference [71]. Obesity and psoriasis have a common pathogenic mechanism involving the fat cells critical for the synthesis of the pro-inflammatory cytokines IL-6 and TNF-α [42]. Because of the presence of these cytokines, macrophages infiltrate into the adipose tissue, and mature macrophages stimulate the secretion of cytokines, resulting in localized primary inflammation. Cytokines also trigger the production of inflammation-related proteins, leading to the low-level systemic inflammation observed in obesity [83, 84]. Obesity through pro-inflammatory pathways can induce the development of psoriasis and is a key factor in the progression of psoriasis in children [85]. Adiponectin levels decrease in obese patients [37, 86]. The diet-induced obesity model (DIO) has decreased adiponectin levels, while a high-fat diet (HFD) increases the frequency of T cells that are positive for IFN-γ and IL-17 [57, 87]. In early studies, meta- analyses showed no clear association between adiponectin levels and BMI [33], but later studies have shown that adiponectin levels are inversely proportional to BMI and low-density lipoprotein (LDL) and cholesterol levels [88,89,90]. In overweight or obese psoriasis patients, adiponectin levels have been observed to be significantly lower than in normal-weight psoriasis patients, but no hypoadiponectinemia was found [50, 70]. The high-molecular-weight adiponectin/total adiponectin ratio is decreased in patients with psoriasis [91]. Moreover, obesity is a predictor of poor treatment outcomes [92]. The use of methotrexate and anti-TNF treatment reduces the risk of comorbidities and is conducive to improvement of psoriasis [82], but anti-TNF-a antibody therapy is associated with an increase in adiposity. During anti-TNF-a treatment, the BMI of patients with psoriasis increase significantly [93]. The BMI increased by three points in patients treated with infliximab for 3 years [94]. Because of this adverse effect, some patients choose to terminate the treatment. Moreover, some studies claim to find no correlation between BMI and the severity of psoriasis [50, 70].

Adiponectin and cardiovascular disease

There is biological plausibility for the link between psoriasis inflammation and cardiovascular disease because there is a common pathogenic mechanism. T cells have a well-defined contributory role to psoriasis. In atherosclerosis, naive T cells are known to play a pro-inflammatory role; once they migrate across the arterial lumen into the intima, they exhibit the characteristics of pro-inflammatory Th1 and Th17 cells [95, 96]. In addition, dyslipidaemia and atherosclerosis have been linked to reduced adiponectin levels [45, 97]. Adiponectin acts on endothelial cells, increasing local nitric oxide production, protecting endothelial function, and inhibiting plaque and thrombosis [98]. Nitric oxide (NO) derived from adipocytes can activate calcium-mediated potassium channel opening in vascular smooth muscle cells (VSMCs) and induce vasodilation [99]. Adiponectin also interacts with forkhead box O1 (FoxO1) to resist oxidative stress and inflammatory arterial damage by forming the FoxO1-C/enhancer-binding protein alpha transcriptional complex [100, 101] and inhibiting TNF-α-induced activation and the adhesion of monocytes to endothelial cells. Therefore, adiponectin may be significant in the prevention of atherosclerosis [102]. In terms of lifestyle, consumption of a HFD can cause an imbalance in the production of biomolecules around perivascular adipose tissue (PVAT), including increased TNF-α and IL-6 and decreased adiponectin levels, which in turn can lead to vascular dysfunction [103]. In high-risk populations with advanced atherosclerosis or other chronic inflammatory diseases, elevated adiponectin levels may be part of a compensatory mechanism that limits further endothelial damage [104, 105]. Patients with psoriasis receiving anti-TNF immune targeting and fumaric acid ester (FAE) have been shown to have a better prognosis [106, 107]. Not only does the PASI score improve, but adiponectin also increases, while high-sensitivity CRP decreases slightly [108]. Olive leaf extract can also significantly improve the expression of key adipogenic genes (such as PPAR, adiponectin and leptin receptors) in HFD-induced adipose tissue and can reverse the endothelial dysfunction observed in the aortic ring of obese mice [109]. This may be a promising new therapy for psoriasis and comorbidities. The role of adiponectin in conditions such as atherosclerosis and obesity has limited its use as a prognostic indicator for cardiovascular disease (CVD) in the general population [110,111,112] and as a biomarker for psoriasis patients with CVD [113].

Adiponectin and diabetes

Psoriasis is associated with type 2 diabetes (T2D) [81]. Although diabetes is the least common component of metabolic syndrome, it is the most common cause of complications of advanced psoriasis [114]. Adipokines such as fetuin A and pro-inflammatory cytokines promote insulin resistance and disorders of energy and lipid metabolism [115]. In psoriasis, in addition to reducing adiponectin levels, fetuin A, may also contribute to excessive keratinocyte proliferation. Whether this is dependent on or independent of insulin desensitisation, it can further enhance metabolic syndrome and skin inflammation in psoriasis [116, 117]. Adiponectin levels in patients with psoriasis without diabetes are significantly higher than those of patients with progressive diabetes [70]. Substantially downregulated expression of adiponectin and its receptors in adipose tissues were also linked with diabetic dyslipidaemic conditions [47]. Experiments have shown that serum insulin levels and the insulin resistance index are positively correlated with the severity of psoriasis [118]. Adiponectin is also a significant regulator of the metabolic environment and energy balance, enhancing insulin sensitivity and reducing liver glycogen production [82, 119]. Therefore, lipid metabolism can be enhanced by increasing lipid clearance from the plasma, which can help improve blood glucose control [120]. In terms of treatment, anti-TNF immune-targeted therapy, such as adalimumab, and skin-directed therapy, such as ultraviolet B phototherapy, can reduce skin inflammation in patients with psoriasis, but adiponectin-induced glucose levels or insulin resistance do not change [55]. Systemic treatment with methotrexate results in a significant decrease in insulin levels and the insulin resistance index [118]. Pitavastatin has been shown to consistently increase plasma adiponectin, and it does not lead to new-onset or statin-induced diabetes [121, 122]. Perhaps statin therapy should be considered earlier in psoriatic patients with low adiponectin values [71].

Adiponectin and other comorbidities

Non-alcoholic fatty liver disease

A correlation between non-alcoholic fatty liver disease (NAFLD) and psoriasis has been reported. Specifically, psoriasis patients have a higher probability of NAFLD [123], while the presence of NAFLD itself may exacerbate the severity of psoriatic skin lesions [124]. NAFLD is often seen in patients with early-onset psoriasis (74.2%), a diagnosis particularly common in patients younger than 40 years of age [114]. Adipokines play an important role in the pathogenesis of NAFLD, particularly adiponectin [115, 125]. Patients with psoriasis complicated by NAFLD have been shown to have lower adiponectin levels than patients with psoriasis alone [126, 127]. An in vivo study has shown that adiponectin deficiency not only increase the expression of NF-κB, but also promote the accumulation of lipid droplets and increase the production of reactive oxygen species (ROS), thereby aggravating liver damage and steatosis in an HFD-induced NAFLD mouse model [128]. In patients with psoriasis, it is reasonable to speculate that the reduction in adiponectin may play a role in promoting the development of NAFLD. In addition, increased expression of NF-κB has been demonstrated in psoriasis [129]. The increase in ROS cause Th1 and Th17 cells and keratinocytes to activate the MAPK, NF-κB and JAK-STAT pathways [130, 131], thereby forming a self-amplification cycle that ultimately leads to excessive keratinocyte proliferation, vascular proliferation and inflammatory infiltration, which is also characteristic of psoriasis [132].

Psoriatic arthritis

Psoriatic arthritis (PsA) and plasma adiponectin levels are negatively correlated [133]. A previous study found that the adiponectin level was significantly higher in PsA patients than in psoriasis patients without arthritis [69]. However, a study of patients with psoriasis with or without PsA found that adiponectin levels were not significantly different [70]. It is possible that most psoriasis studies do not appropriately control for parameters, such as the presence of PsA, which may contribute to the inconsistency of the results if the groups are not properly adjusted [73]. The effect of lifestyle has also been studied, and it was found that alcohol consumption obviously affects the negative correlation between adiponectin and PsA occurrence [133].

Mental disorders

Psoriasis increases the risk of mental disorders, including depression, anxiety and suicide [134]. In addition to the psychological stress caused by psoriasis, it has been reported that inflammatory cytokines are related to mood disorders, including elevated levels of cytokines, including TNF-a, IL-6 and IL-1 [135, 136]. Anti-depressants reduce the central nervous system’s inflammatory response and the levels of inflammatory cytokines, such as FAE [135, 137]. This not only improves the psoriasis and adiponectin levels but also efficiently reduces depression symptoms [107]. It can be speculated that the increase in pro-inflammatory cytokines caused by the decrease in adiponectin levels in patients with psoriasis may be one of the causes of depression.

Adiponectin and anti-psoriasis treatments

In terms of treatment, secukinumab and etanercept have no relevant effect on adiponectin levels and they do not change the adiponectin level [70]. This may highlight that adiponectin levels are not closely related to PASI, a result consistent with other local and/or systemic treatment studies, except for analyses of secukinumab or other anti-IL-17 inhibitors [138, 139]. Patients using anti-inflammatory drugs or phototherapy may also have increased adiponectin levels [50, 140]. After mildly affected patients with no evidence of psoriatic arthritis received systemic methotrexate treatment, the PASI score was significantly reduced, but this treatment did not affect the serum adiponectin level [90]. During TNF-α treatment, an increase in adiponectin levels can also be observed [141]. Xue Li et al. found that hesperidin (Hes) can significantly improve psoriasis-like skin damage in mice and inhibit the proliferation of human immortalized keratinocytes (HaCaT) by inhibiting the activation of the IRS-1/ERK1/2 signalling pathway. After Hes administration, adiponectin levels in mice were significantly upregulated, and PASI scores were remarkably reduced. The secretion of pro-inflammatory factors in skin lesions, epidermal hyperproliferation and differentiation, and epidermal thickness were also reduced [142]. In addition, the level of IL-17A decreased significantly and the level of adiponectin increased significantly after treatment with Cal/BD aerosol foam. It is worth noting that there was a significant correlation between the improvement in PASI and the level of IL-17A [143]. Therefore, future research should examine the relationship between adiponectin and PASI and determine whether psoriasis can be treated by increasing adiponectin levels.

Study strength and limitations

This review comprehensively summarizes the possible role of adiponectin as an immunomodulator and the correlation between adiponectin levels and various clinical parameters, emphasizing that adiponectin is likely to become a new target for the treatment of psoriasis.


There is a complex relationship between psoriasis and fat. Studies on adipokines, particularly adiponectin, and their cytokine-related mechanisms are still insufficient, and information is lacking on whether these cytokines or their profiles can serve as biomarkers for psoriasis. Nevertheless, the importance of adiponectin in psoriasis is still of concern. With increasing research, the relationship between adiponectin and various systems of the body is becoming clearer, and changes in the expression of adiponectin can provide some guidance for patients with psoriasis regarding treatment. In the past, researchers have been more inclined to discuss systemic adiponectin, and the expression of local adiponectin in psoriasis may be more worthy of attention in the future. At the same time, it is also surprising that adiponectin may play a role as a lipid carrier, which provides a new direction for research. Currently, PASI is the gold standard for assessing the severity of psoriasis and its affected body regions, and the relationship between adiponectin and PASI should therefore be further clarified. In the evaluation of treatment, patient weight must be considered because there is a correlation between psoriasis and different comorbidities for which weight evaluation is valuable. The use of prior medications and the length of observation must also be considered, which may affect our judgement about the relationship between adiponectin and the course of psoriasis and even the evaluation of treatment efficacy. Furthermore, emphasis should also be placed on environmental and social factors involved in the disease, rather than focusing only on genetic and immune pathways. From a holistic perspective, a combination of biotherapy and measures to improve lifestyle can effectively alleviate the metabolic status of patients with psoriasis, including altering their adiponectin levels, which is indispensable for ameliorating the functional disorders of various systems in patients with psoriasis.

Availability of data and materials

Not applicable.



Adenosine monophosphate protein kinase

p38 MAPK:

p38 mitogen-activated protein kinase


Peroxisome proliferator-activated receptor alpha


Nuclear factor κB




Tumor necrosis factor




Sedimentation rate


C-reactive protein


Sebaceous glands


Psoriasis area and severity index




Human immortalized keratinocytes


Diet-induced obesity


High-fat diet


Body mass index


Low density lipoprotein


Vascular smooth muscle cells

FoxO 1:

Forkhead box O1


Perivascular adipose tissue


Fumaric acid ester


Cardiovascular disease


Type 2 Diabetes


Non-alcoholic fatty liver disease


Psoriatic arthritis


Nitric oxide


subcutaneous White adipose tissue


C1q/TNF related protein


Reactive oxygen species


  1. 1.

    Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5):490–5.

    Article  PubMed  Google Scholar 

  4. 4.

    Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  5. 5.

    Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23 discussion ii24–5.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–21.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–7.

    Article  PubMed  Google Scholar 

  10. 10.

    Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980-1983. Arch Dermatol. 1991;127(8):1184–7.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Jacob C, Meier F, Neidhardt K, Jugl SM, Walker J, Braun S, et al. Epidemiology and costs of psoriasis in Germany - a retrospective claims data analysis. Value Health. 2016;19(7):A566.

    Google Scholar 

  12. 12.

    Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol. 2017;97(7):808–12.

    Article  PubMed  Google Scholar 

  13. 13.

    Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176(3):650–8.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Kubanova A, Kubanov A, Melekhina L, Bogdanova EV. The assessment of the incidence of skin disorders in Russian Federation in 2003–2016. Vestnik dermatologii i venerologii. 2017;93(6):22–33.

    Article  Google Scholar 

  15. 15.

    Schonmann Y, Ashcroft DM, Iskandar IYK, Parisi R, Sde-Or S, Comaneshter D, et al. Incidence and prevalence of psoriasis in Israel between 2011 and 2017. J Eur Acad Dermatol Venereol. 2019;33(11):2075–81.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Yiu ZZN, Parisi R, Lunt M, Warren RB, Griffiths CEM, Langan SM, et al. Risk of hospitalisation and death due to infection in people with psoriasis: a population-based cohort study using the clinical practice research datalink. Br J Dermatol. 2021;184(1):178–86.

  19. 19.

    Amanat M, Salehi M, Rezaei N. Neurological and psychiatric disorders in psoriasis. Rev Neurosci. 2018;29(7):805–13.

    PubMed  Article  Google Scholar 

  20. 20.

    Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30(2):282–7.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9(2):191–200.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Polito R, Nigro E, Messina A, Monaco ML, Monda V, Scudiero O, et al. Adiponectin and orexin-a as a potential immunity link between adipose tissue and central nervous system. Front Physiol. 2018;9:982.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A. 2004;101(28):10302–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Ye JJ, Bian X, Lim J, Medzhitov R. Adiponectin and related C1q/TNF-related proteins bind selectively to anionic phospholipids and sphingolipids. Proc Natl Acad Sci U S A. 2020;117(29):17381–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–9.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8(3):1031–63.

    Article  PubMed  Google Scholar 

  29. 29.

    Wang X, Chen Q, Pu H, Wei Q, Duan M, Zhang C, et al. Adiponectin improves NF-kappaB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice. Lipids Health Dis. 2016;15:33.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  30. 30.

    Schäffler A, Buechler C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. 2012;23(4):194–204.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J. 2008;416(2):161–77.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84–9.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol. 2013;40(6):438–42.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Bulur I, Erdogan HK, Kocaturk E, Saracoglu ZN, Alatas O, Yildiz P, et al. The role of irisin in the relationship between psoriasis and insulin resistance. G Ital Dermatol Venereol. 2018;153(4):477–82.

    Article  PubMed  Google Scholar 

  35. 35.

    Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649–55.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in psoriasis. Front Immunol. 2019;10:1507.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010;59(2):143–5.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Bai F, Zheng W, An J, Dong Y, Wang J, Garstka MA, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9:1266–78.

    PubMed  Article  Google Scholar 

  40. 40.

    Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? Exp Dermatol. 2012;21(1):43–7.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55(1):62–3.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M, et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res. 2019;68(7):557–67.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Campanati A, Ganzetti G, Giuliodori K, Marra M, Bonfigli A, Testa R, et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-alpha inhibitors: results of a retrospective analysis. Int J Dermatol. 2015;54(7):839–45.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671–4.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121(2):326–30.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Baran A, Flisiak I, Jaroszewicz J, Swiderska M. Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatol Alergol. 2015;32(2):101–6.

    Article  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Ghoshal K, Chatterjee T, Chowdhury S, Sengupta S, Bhattacharyya M. Adiponectin genetic variant and expression coupled with lipid peroxidation reveal new signatures in diabetic dyslipidemia. Biochem Genet. 2021;59(3):781–98.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6(1):13–21.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20(2):81–7.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Bavoso NC, Pinto JM, Soares MMS, Diniz MDS, Teixeira Junior AL. Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects - cases and controls. An Bras Dermatol. 2019;94(2):192–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Shibata S, Tada Y, Hau C, Tatsuta A, Yamamoto M, Kamata M, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164(3):667–70.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(12):1386–94.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9; quiz 920.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159(5):1207–8.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.

    Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Campanati A, Orciani M, Consales V, Lazzarini R, Ganzetti G, Di Benedetto G, et al. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Arch Dermatol Res. 2014;306(10):915–20.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Surendar J, Frohberger SJ, Karunakaran I, Schmitt V, Stamminger W, Neumann AL, et al. Adiponectin limits IFN-gamma and IL-17 producing CD4 T cells in obesity by restraining cell intrinsic glycolysis. Front Immunol. 2019;10:2555.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from gammadelta-T cells. Nat Commun. 2015;6(1):7687.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Kim JW, Lee YS, Seol DJ, Cho IJ, Ku SK, Choi JS, et al. Anti-obesity and fatty liver-preventing activities of Lonicera caerulea in high-fat diet-fed mice. Int J Mol Med. 2018;42(6):3047–64.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature. 2009;462(7275):925–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Singh RK, Dagnino L. CDH1 regulates E2F1 degradation in response to differentiation signals in keratinocytes. Oncotarget. 2017;8(3):4977–93.

    Article  PubMed  Google Scholar 

  63. 63.

    Lee JH, Moon JH, Lee YJ, Park SY. SIRT1, a class III histone deacetylase, regulates LPS-induced inflammation in human keratinocytes and mediates the anti-inflammatory effects of Hinokitiol. J Invest Dermatol. 2017;137(6):1257–66.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Saunders N, Dahler A, Jones S, Smith R, Jetten A. Interferon-gamma as a regulator of squamous differentiation. J Dermatol Sci. 1996;13(2):98–106.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Jin T, Kim MJ, Heo WI, Park KY, Choi SY, Lee MK, et al. Adiponectin corrects premature cellular senescence and normalizes antimicrobial peptide levels in senescent keratinocytes. Biochem Biophys Res Commun. 2016;477(4):678–84.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Zhang M, Zhang X. The role of PI3K/AKT/FOXO signaling in psoriasis. Arch Dermatol Res. 2019;311(2):83–91.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Singh V, Ubaid S. Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation. Inflammation. 2020;43(5):1589–98.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Kovacs D, Lovaszi M, Poliska S, Olah A, Biro T, Veres I, et al. Sebocytes differentially express and secrete adipokines. Exp Dermatol. 2016;25(3):194–9.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013;72(12):1956–61.

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    Gerdes S, Pinter A, Biermann M, Papavassilis C, Reinhardt M. Adiponectin levels in a large pooled plaque psoriasis study population. J Dermatolog Treat. 2020;31(5):531–4.

  71. 71.

    Chan WSA, Liew CF, Theng CTS, Oon HH. Serum adiponectin levels and their association with Cardiometabolic risk factors in patients with psoriasis. Cureus. 2020;12(5):e8128.

    PubMed  PubMed Central  Google Scholar 

  72. 72.

    Kruglikov IL, Scherer PE, Wollina U. Are dermal adipocytes involved in psoriasis? Exp Dermatol. 2016;25(10):812–3.

    Article  PubMed  Google Scholar 

  73. 73.

    Kruglikov IL, Wollina U. Local effects of adipose tissue in psoriasis and psoriatic arthritis. Psoriasis (Auckl). 2017;7:17–25.

    CAS  Article  Google Scholar 

  74. 74.

    Brembilla NC, Boehncke WH. Dermal adipocytes' claim for fame in psoriasis. Exp Dermatol. 2017;26(5):392–3.

    Article  PubMed  Google Scholar 

  75. 75.

    Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol. 1993;100(3):225–8.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Zhang LJ, Guerrero-Juarez CF, Hata T, Bapat SP, Ramos R, Plikus MV, et al. Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin infection. Science. 2015;347(6217):67–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Clausen ML, Slotved HC, Krogfelt KA, Andersen PS, Agner T. In vivo expression of antimicrobial peptides in atopic dermatitis. Exp Dermatol. 2016;25(1):3–9.

    CAS  Article  PubMed  Google Scholar 

  78. 78.

    Dattola A, Altobelli S, Marsico S, Plastina D, Nistico SP, Cavallo A, et al. Hypodermal adipose tissue Sonoelastography for monitoring treatment response in patients with plaque psoriasis. Photomed Laser Surg. 2017;35(9):484–91.

    Article  PubMed  Google Scholar 

  79. 79.

    Kruglikov IL, Wollina U. The role of subcutaneous adipose tissue in psoriasis. J Biol Regul Homeost Agents. 2018;32(1):159–61.

    CAS  PubMed  Google Scholar 

  80. 80.

    Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Goolam Mahyoodeen N. N.J. Crowther, L. Pillay, T. Snyman, M. Toman, S. Daya, et al., relationship of visceral fat and Adipokines with Cardiometabolic diseases in psoriasis. Acta Derm Venereol. 2019;99(13):1218–23.

    CAS  Article  PubMed  Google Scholar 

  82. 82.

    Rodriguez-Cerdeira C, Cordeiro-Rodriguez M, Carnero-Gregorio M, Lopez-Barcenas A, Martinez-Herrera E, Fabbrocini G, et al. Biomarkers of inflammation in obesity-psoriatic patients. Mediat Inflamm. 2019;2019:7353420.

    Article  CAS  Google Scholar 

  83. 83.

    Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, et al. The roles of Adipokines, Proinflammatory cytokines, and adipose tissue macrophages in obesity-associated insulin resistance in modest obesity and early metabolic dysfunction. PLoS One. 2016;11(4):e0154003.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  85. 85.

    Tollefson MM, Van Houten HK, Asante D, Yao X, Maradit Kremers H. Association of Psoriasis with Comorbidity Development in children with psoriasis. JAMA Dermatol. 2018;154(3):286–92.

    Article  PubMed  PubMed Central  Google Scholar 

  86. 86.

    Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39(3):212–8.

    CAS  Article  PubMed  Google Scholar 

  87. 87.

    Son M, Oh S, Lee HS, Chung DM, Jang JT, Jeon YJ, et al. Ecklonia cava extract attenuates endothelial cell dysfunction by modulation of inflammation and brown adipocyte function in perivascular fat tissue. Nutrients. 2019;11(11):2795.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  88. 88.

    Oh YJ, Lim HK, Choi JH, Lee JW, Kim NI. Serum leptin and adiponectin levels in Korean patients with psoriasis. J Korean Med Sci. 2014;29(5):729–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Warnecke C, Manousaridis I, Herr R, Terris DD, Goebeler M, Goerdt S, et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol. 2011;21(5):761–70.

    Article  PubMed  Google Scholar 

  90. 90.

    Coban M, Tasli L, Turgut S, Ozkan S, Tunc Ata M, Akin F. Association of Adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol. 2016;28(1):74–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91.

    Toussirot E, Aubin F, Desmarets M, Wendling D, Augé B, Gillard J, et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology (Oxford). 2020;60(6):2816–25.

  92. 92.

    Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63(6):1058–69.

    Article  PubMed  Google Scholar 

  93. 93.

    Peluso I, Palmery M. The relationship between body weight and inflammation: lesson from anti-TNF-α antibody therapy. Hum Immunol. 2016;77(1):47–53.

    CAS  PubMed  Article  Google Scholar 

  94. 94.

    Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):e186–90.

    CAS  Article  PubMed  Google Scholar 

  95. 95.

    Shlyankevich J, Mehta NN, Krueger JG, Strober B, Gudjonsson JE, Qureshi AA, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med. 2014;127(12):1148–53.

    Article  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019;38(1):33–54.

    Article  PubMed  Google Scholar 

  97. 97.

    Li RC, Krishnamoorthy P, DerOhannessian S, Doveikis J, Wilcox M, Thomas P, et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol. 2014;39(1):19–24.

    Article  PubMed  Google Scholar 

  98. 98.

    Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292(4):H1655–63.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Darios ES, Winner BM, Charvat T, Krasinksi A, Punna S, Watts SW. The adipokine chemerin amplifies electrical field-stimulated contraction in the isolated rat superior mesenteric artery. Am J Physiol Heart Circ Physiol. 2016;311(2):H498–507.

    Article  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Lu CL, Liao MT, Hou YC, Fang YW, Zheng CM, Liu WC, et al. Sirtuin-1 and its relevance in vascular calcification. Int J Mol Sci. 2020;21(5):1593.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  101. 101.

    Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem. 2006;281(52):39915–24.

    CAS  Article  PubMed  Google Scholar 

  102. 102.

    Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473–6.

    CAS  Article  PubMed  Google Scholar 

  103. 103.

    Almabrouk TA, Ewart MA, Salt IP, Kennedy S. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol. 2014;171(3):595–617.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  104. 104.

    Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27(19):2300–9.

    CAS  Article  PubMed  Google Scholar 

  105. 105.

    Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93(4):1489–96.

    CAS  Article  PubMed  Google Scholar 

  106. 106.

    Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50.

    CAS  Article  PubMed  Google Scholar 

  107. 107.

    Schmieder A, Poppe M, Hametner C, Meyer-Schraml H, Schaarschmidt ML, Findeisen P, et al. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study. Arch Dermatol Res. 2015;307(5):413–24.

    CAS  PubMed  Article  Google Scholar 

  108. 108.

    Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25(10):1187–93.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Vezza T, Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, Romero M, Sanchez M, et al. The metabolic and vascular protective effects of olive (Olea europaea L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties. Pharmacol Res. 2019;150:104487.

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Woodward L, Akoumianakis I, Antoniades C. Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol. 2017;174(22):4007–20.

    CAS  PubMed  Article  Google Scholar 

  111. 111.

    Ruscica M, Baragetti A, Catapano AL, Norata GD. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Nutr Metab Cardiovasc Dis. 2017;27(5):379–95.

    CAS  Article  PubMed  Google Scholar 

  112. 112.

    Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28(4):347–54.

    CAS  Article  PubMed  Google Scholar 

  113. 113.

    Kaur S, Kingo K, Zilmer M. Psoriasis and cardiovascular risk-do promising new biomarkers have clinical impact? Mediat Inflamm. 2017;2017:7279818.

    Article  CAS  Google Scholar 

  114. 114.

    Xu X, Su L, Gao Y, Ding Y. The prevalence of nonalcoholic fatty liver disease and related metabolic comorbidities was associated with age at onset of moderate to severe plaque psoriasis: a cross-sectional study. PLoS One. 2017;12(1):e0169952.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  115. 115.

    Panera N, Della Corte C, Crudele A, Stronati L, Nobili V, Alisi A. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Exp Rev Gastroenterol Hepatol. 2016;10(3):393–403.

    CAS  Article  Google Scholar 

  116. 116.

    Wolk K, Sabat R. Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305–17.

    CAS  Article  PubMed  Google Scholar 

  117. 117.

    Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, et al. Fetuin-a induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  118. 118.

    Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa DM. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2015;29(1):69–76.

    CAS  PubMed  Article  Google Scholar 

  119. 119.

    Kong Y, Zhang S, Wu R, Su X, Peng D, Zhao M, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019;18(1):171.

    Article  PubMed  PubMed Central  Google Scholar 

  120. 120.

    Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4542–8.

    CAS  Article  PubMed  Google Scholar 

  121. 121.

    Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1–27.

    Article  PubMed  Google Scholar 

  122. 122.

    Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131–49.

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70(3):517–24.

    Article  PubMed  Google Scholar 

  124. 124.

    Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778–86.

    CAS  Article  PubMed  Google Scholar 

  125. 125.

    Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–91.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  126. 126.

    Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41(3):293–300.

    CAS  Article  PubMed  Google Scholar 

  127. 127.

    Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179(1):16–29.

    CAS  Article  PubMed  Google Scholar 

  128. 128.

    Dong Z, Zhuang Q, Ye X, Ning M, Wu S, Lu L, et al. Adiponectin inhibits NLRP3 Inflammasome activation in nonalcoholic steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways. Front Med (Lausanne). 2020;7:546445.

    Article  Google Scholar 

  129. 129.

    Lin X, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016;50(6):585–95.

    CAS  Article  PubMed  Google Scholar 

  130. 130.

    Becatti M, Barygina V, Mannucci A, Emmi G, Prisco D, Lotti T, et al. Sirt1 protects against oxidative stress-induced apoptosis in fibroblasts from psoriatic patients: A new insight into the pathogenetic mechanisms of psoriasis. Int J Mol Sci. 2018;19(6):1572.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  131. 131.

    Lei Y, Wang K, Deng L, Chen Y, Nice EC, Huang C. Redox regulation of inflammation: old elements, a new story. Med Res Rev. 2015;35(2):306–40.

    CAS  Article  PubMed  Google Scholar 

  132. 132.

    Xu F, Xu J, Xiong X, Deng Y. Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep. 2019;24(1):70–4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  133. 133.

    Johnson CM, Fitch K, Merola JF, Han J, Qureshi AA, Li WQ. Plasma levels of tumour necrosis factor-alpha and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis. Br J Dermatol. 2019;181(2):379–80.

    CAS  Article  PubMed  Google Scholar 

  134. 134.

    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5.

    Article  PubMed  PubMed Central  Google Scholar 

  135. 135.

    Hashmi AM, Butt Z, Umair M. Is depression an inflammatory condition? A review of available evidence. J Pak Med Assoc. 2013;63(7):899–906.

    PubMed  Google Scholar 

  136. 136.

    Das R, Emon MPZ, Shahriar M, Nahar Z, Islam SMA, Bhuiyan MA, et al. Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder. Psychiatry Res. 2021;295:113568.

    CAS  Article  PubMed  Google Scholar 

  137. 137.

    Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010;7(1):30.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  138. 138.

    Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):273–81.

    CAS  PubMed  Google Scholar 

  139. 139.

    Baran A, Flisiak I, Jaroszewicz J, Świderska M. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. J Dermatolog Treat. 2015;26(2):134–8.

    CAS  Article  PubMed  Google Scholar 

  140. 140.

    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11(6):423–32.

    Article  PubMed  Google Scholar 

  141. 141.

    Corrado A, Colia R, Rotondo C, Sanpaolo E, Cantatore FP. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α. Curr Med Res Opin. 2019;35(12):2197–205.

    CAS  PubMed  Article  Google Scholar 

  142. 142.

    Li X, Xie X, Zhang L, Meng Y, Li N, Wang M, et al. Hesperidin inhibits keratinocyte proliferation and imiquimod-induced psoriasis-like dermatitis via the IRS-1/ERK1/2 pathway. Life Sci. 2019;219:311–21.

    CAS  PubMed  Article  Google Scholar 

  143. 143.

    Ropke M, Bulai Livideanu C, Kaldate R, Snel A, Paul C. Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. Br J Dermatol. 2018;178(1):e33–4.

    CAS  Article  PubMed  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information




RB and SF wrote the manuscript. AP edited the manuscript. RW and PZ revised the manuscript. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhang Peng or Fu Siqi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ruiyang, B., Panayi, A., Ruifang, W. et al. Adiponectin in psoriasis and its comorbidities: a review. Lipids Health Dis 20, 87 (2021).

Download citation


  • Adiponectin
  • Comorbidity
  • Immunity
  • Psoriasis
  • T lymphocytes